TickerFacts.

A business in context

SPRY research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-09-07 · 8010 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-09-01 · 0002149973-26-000004

  2. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-349140

  3. 8-K · Current report

    Report date 2026-08-13 · 0001193125-26-349127 · Items 2.02,9.01

  4. 8-K · Current report

    Report date 2026-07-15 · 0001193125-26-307773 · Items 5.02

  5. 8-K · Current report

    Report date 2026-07-06 · 0001193125-26-297554 · Items 5.02

  6. 4 · Ownership change

    Report date 2026-07-01 · 0002135296-26-000007

  7. 4 · Ownership change

    Report date 2026-06-24 · 0001952533-26-000002

  8. 4 · Ownership change

    Report date 2026-06-24 · 0001580787-26-000004

  9. 4 · Ownership change

    Report date 2026-06-24 · 0001575408-26-000002

  10. 4 · Ownership change

    Report date 2026-06-24 · 0001551891-26-000002

  11. 4 · Ownership change

    Report date 2026-06-24 · 0001357522-26-000005

  12. 4 · Ownership change

    Report date 2026-06-24 · 0001268854-26-000002

  13. 8-K · Current report

    Report date 2026-06-24 · 0001193125-26-282994 · Items 5.07

  14. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-225142

  15. 8-K · Current report

    Report date 2026-05-15 · 0001193125-26-225055 · Items 2.02,7.01,9.01

  16. 8-K · Current report

    Report date 2026-05-12 · 0001193125-26-220671 · Items 5.02,9.01

  17. DEF 14A · Proxy statement

    Report date 2026-06-24 · 0001193125-26-191433

  18. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-097478

  19. 8-K · Current report

    Report date 2026-03-09 · 0001193125-26-097467 · Items 2.02,7.01,9.01

  20. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-273111

  21. 8-K · Current report

    Report date 2025-11-10 · 0001193125-25-273107 · Items 2.02,7.01,9.01

  22. 8-K · Current report

    Report date 2025-09-29 · 0001193125-25-223228 · Items 1.01,2.03,9.01

  23. 8-K · Current report

    Report date 2025-08-13 · 0001193125-25-190202 · Items 8.01

  24. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-107618

  25. 8-K · Current report

    Report date 2025-08-13 · 0000950170-25-107617 · Items 2.02,7.01,9.01

  26. 8-K · Current report

    Report date 2025-06-25 · 0001193125-25-148922 · Items 5.07

  27. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-070900

  28. 8-K · Current report

    Report date 2025-05-14 · 0000950170-25-070899 · Items 2.02,9.01

  29. 8-K · Current report

    Report date 2025-05-02 · 0001193125-25-110696 · Items 1.01

  30. DEF 14A · Proxy statement

    Report date 2025-06-25 · 0000950170-25-060075

  31. 10-K · Annual report

    Report date 2024-12-31 · 0000950170-25-042320

  32. 8-K · Current report

    Report date 2025-03-20 · 0000950170-25-042317 · Items 2.02,9.01

  33. 8-K · Current report

    Report date 2025-03-05 · 0001193125-25-047351 · Items 8.01

  34. 8-K · Current report

    Report date 2025-01-13 · 0001193125-25-005014 · Items 2.02,7.01,9.01

  35. 10-Q/A · Quarterly report

    Report date 2024-09-30 · 0001193125-24-272445

  36. 10-Q · Quarterly report

    Report date 2024-09-30 · 0000950170-24-125924

  37. 8-K · Current report

    Report date 2024-11-13 · 0000950170-24-125921 · Items 2.02,9.01

  38. 8-K · Current report

    Report date 2024-11-09 · 0001193125-24-255185 · Items 1.01

  39. 8-K · Current report

    Report date 2024-10-08 · 0001193125-24-237191 · Items 1.01

  40. 8-K · Current report

    Report date 2024-09-17 · 0001193125-24-223676 · Items 1.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-09-07 · 2026 Q2: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 2 transaction rows2SGrant / award: 9 transaction rows9AExercise / conversion: 2 transaction rows2MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

13 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-06-24
2026-06-26
Kelly MichaelA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
Shah PratikA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
Islam SaqibA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
Shawver LauraA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
Thompson Peter A.A · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
SAUNDERS BRENT LA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.A · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
SCHNEIDER PHILLIP MA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-24
2026-06-26
Dadoo RajeevA · Grant / award
Acquired
Stock Option (right to buy)
Derivative security
30000.00.0
2026-06-12
2026-06-12
Karas Eric
10b5-1 checkbox reported
M · Exercise / conversion
Acquired
Common Stock25000.01.5
2026-06-12
2026-06-12
Karas Eric
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock25000.010.0
2026-06-12
2026-06-12
Karas Eric
10b5-1 checkbox reported
M · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
25000.00.0
2026-06-12
2026-06-12
Fitzpatrick Alexander A
10b5-1 checkbox reported
S · Sale
Disposed
Common Stock3355.010.0

Identity & relationships

Wikidata structured data · retrieved 2026-09-07 · 1611 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001671858ARS Pharmaceuticals, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-09-07 · 1177 checked identities; 0 unavailable records

Search names and former names

View Wikidata identity and references ↗

  • Silverback Therapeutics · alias · wikidata
  • Silverback Therapeutics, Inc. · former SEC name · 2016-04-12 to 2022-11-08
Explore headquarters map ↗

Revenue in constant purchasing power

USD revenue expressed in 2026-07 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

Year endedReported USD revenueCPI-adjusted USD revenue
2024-12-31$89.15M$94.90M
2023-12-31$30.0K$32.9K
2022-12-31$1.32M$1.50M
2021-12-31$5.51M$6.78M

Bureau of Labor Statistics · retrieved 2026-09-07 · 9 selected series; gaps remain missing

Explore the CPI history ↗